The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer
The Oncology Institute (NASDAQ: TOI) has appointed Dr. Jeffrey Langsam as its new enterprise Chief Clinical Officer (CCO), effective May 13th, 2025. In this role, Dr. Langsam will oversee therapeutics, including pathway and procurement decisions, utilization management, and MSO practice clinical engagement.
Dr. Langsam joins TOI from Cigna Healthcare, where he served as National Director of Oncology and Senior Medical Director in the Specialty Pharmacy Division. His previous experience includes roles as Regional Medical Director at Aetna and clinical faculty at the University of Connecticut, where he practiced as an oncologist.
The appointment comes as TOI experiences acceleration in new value-based partnerships and growth in its MSO model across the country.
L'Istituto di Oncologia (NASDAQ: TOI) ha nominato il Dott. Jeffrey Langsam come nuovo Chief Clinical Officer (CCO) aziendale, con decorrenza dal 13 maggio 2025. In questo ruolo, il Dott. Langsam supervisionerà le terapie, incluse le decisioni riguardanti i percorsi terapeutici e gli approvvigionamenti, la gestione dell'utilizzo e l'impegno clinico nelle pratiche MSO.
Il Dott. Langsam arriva a TOI da Cigna Healthcare, dove ha ricoperto il ruolo di Direttore Nazionale di Oncologia e Direttore Medico Senior nella Divisione Specialty Pharmacy. La sua esperienza precedente include incarichi come Direttore Medico Regionale presso Aetna e docente clinico presso l'Università del Connecticut, dove ha esercitato come oncologo.
La nomina avviene in un momento in cui TOI sta accelerando le nuove partnership basate sul valore e la crescita del suo modello MSO a livello nazionale.
El Instituto de Oncología (NASDAQ: TOI) ha nombrado a Dr. Jeffrey Langsam como su nuevo Director Clínico Empresarial (CCO), con efecto a partir del 13 de mayo de 2025. En este cargo, el Dr. Langsam supervisará las terapias, incluyendo decisiones sobre rutas y adquisiciones, la gestión de la utilización y el compromiso clínico en la práctica MSO.
El Dr. Langsam se une a TOI procedente de Cigna Healthcare, donde fue Director Nacional de Oncología y Director Médico Senior en la División de Farmacia Especializada. Su experiencia previa incluye roles como Director Médico Regional en Aetna y profesor clínico en la Universidad de Connecticut, donde ejerció como oncólogo.
El nombramiento se produce en un momento en que TOI está acelerando nuevas asociaciones basadas en el valor y el crecimiento de su modelo MSO en todo el país.
종양학 연구소(NASDAQ: TOI)는 제프리 랭샘 박사를 2025년 5월 13일부터 새로운 기업 최고임상책임자(CCO)로 임명했습니다. 이 역할에서 랭샘 박사는 치료법, 경로 및 조달 결정, 이용 관리, MSO 실무 임상 참여를 감독하게 됩니다.
랭샘 박사는 Cigna Healthcare에서 종양학 국가 이사 및 전문 약국 부서 수석 의료 이사로 근무한 경력이 있습니다. 이전에는 Aetna의 지역 의료 이사와 코네티컷 대학교 임상 교수로서 종양학자로 활동했습니다.
이번 임명은 TOI가 전국적으로 가치 기반의 새로운 파트너십과 MSO 모델의 성장을 가속화하는 시점에 이루어졌습니다.
L'Institut d'Oncologie (NASDAQ : TOI) a nommé le Dr Jeffrey Langsam en tant que nouveau Chief Clinical Officer (CCO) de l'entreprise, à compter du 13 mai 2025. Dans ce rôle, le Dr Langsam supervisera les thérapies, y compris les décisions relatives aux parcours et à l'approvisionnement, la gestion de l'utilisation et l'engagement clinique des pratiques MSO.
Le Dr Langsam rejoint TOI en provenance de Cigna Healthcare, où il était Directeur National de l'Oncologie et Directeur Médical Senior dans la division Pharmacie Spécialisée. Son expérience antérieure comprend des postes de Directeur Médical Régional chez Aetna et de membre du corps professoral clinique à l'Université du Connecticut, où il exerçait en tant qu'oncologue.
Cette nomination intervient alors que TOI connaît une accélération de nouveaux partenariats basés sur la valeur et une croissance de son modèle MSO à l'échelle nationale.
Das Onkologie-Institut (NASDAQ: TOI) hat Dr. Jeffrey Langsam zum neuen Chief Clinical Officer (CCO) des Unternehmens ernannt, mit Wirkung zum 13. Mai 2025. In dieser Funktion wird Dr. Langsam die therapeutischen Maßnahmen, einschließlich der Entscheidungen zu Behandlungspfaden und Beschaffung, das Nutzungsmanagement sowie das klinische Engagement der MSO-Praxis überwachen.
Dr. Langsam kommt von Cigna Healthcare, wo er als Nationaler Direktor für Onkologie und Senior Medical Director in der Specialty Pharmacy Division tätig war. Seine vorherigen Positionen umfassen die Rolle des Regional Medical Director bei Aetna und eine klinische Lehrtätigkeit an der University of Connecticut, wo er als Onkologe praktizierte.
Die Ernennung erfolgt zu einem Zeitpunkt, an dem TOI eine Beschleunigung neuer wertbasierter Partnerschaften und ein Wachstum seines MSO-Modells im ganzen Land erlebt.
- Strategic hire with extensive experience in both clinical oncology and healthcare management
- Appointment aligns with company's expansion of value-based partnerships and MSO model
- Dr. Langsam brings valuable expertise in Oncology and Specialty Pharmacy to scale therapeutic decision-making
- None.
CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Director of Oncology and a Senior Medical Director in the Specialty Pharmacy Division. He previously served as a Regional Medical Director at Aetna, and was clinical faculty at the University of Connecticut where he was a practicing oncologist for many years.
“We are ecstatic that Dr. Langsam is joining our already impressive group of clinical leaders at TOI as our next CCO.” said Daniel Virnich, CEO of The Oncology Institute. “As we see acceleration in new value-based partnerships across the country and growth in our MSO model, Dr. Langsam’s deep expertise in Oncology and Specialty Pharmacy will be pivotal in scaling our therapeutic decision-making model across the enterprise and building a high-value engaged MSO network.”
“I couldn’t be more excited about joining the senior leadership team at TOI as CCO”, commented Dr. Langsam. “TOI has been leading value-based community oncology for many years, and acceleration in risk-based contracts and service offerings makes this a critical moment for the organization to continue scaling its clinical model to provide even greater benefits to patients and payor partners.”
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better.
For more information, visit www.theoncologyinstitute.com
Contacts
Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com
Investors
Solebury Strategic Communications
investors@theoncologyinstitute.com
FAQ
Who is the new Chief Clinical Officer (CCO) of The Oncology Institute (TOI)?
What was Dr. Jeffrey Langsam's previous role before joining TOI?
What will be Dr. Langsam's responsibilities as CCO at TOI?
Why did TOI stock (NASDAQ: TOI) appoint a new Chief Clinical Officer?
